Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables - Net: 2020-2023

Historic Receivables - Net for Revolution Medicines (RVMD) over the last 4 years, with Dec 2023 value amounting to $1.3 million.

  • Revolution Medicines' Receivables - Net fell 73.16% to $1.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.3 million, marking a year-over-year decrease of 73.16%. This contributed to the annual value of $1.3 million for FY2023, which is 73.16% down from last year.
  • Latest data reveals that Revolution Medicines reported Receivables - Net of $1.3 million as of FY2023, which was down 73.16% from $4.7 million recorded in FY2022.
  • Revolution Medicines' Receivables - Net's 5-year high stood at $6.4 million during FY2020, with a 5-year trough of $1.3 million in FY2023.
  • Its 3-year average for Receivables - Net is $4.0 million, with a median of $4.7 million in 2022.
  • Data for Revolution Medicines' Receivables - Net shows a maximum YoY slumped of 73.16% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Revolution Medicines' Receivables - Net stood at $6.4 million in 2020, then decreased by 7.26% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then slumped by 73.16% to $1.3 million in 2023.